Nisa Maruthur, MD, MHS, is a primary care physician and associate professor of medicine at Johns Hopkins University,with a deep commitment to research aimed at improving community-based diabetes prevention. As a member of the writing committee for the the new American Diabetes Association/ European Association for the Study of Diabetes consensus report on management of hyperglycemia in type 2 diabetes, she highlighted for Patient Care® the need for systemic and institutional change called for in the consensus report.
ADA, EASD 2022 Consensus Report from the Primary Care Point of View, with Nisa Maruthur, MD, MHS
Primary Care Would Benefit from Education on Use of SGLT-2 Inhibitors, GLP-1 Mimetics: Nisa Maruthur, MD, MHS
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
2 Commerce Drive
Cranbury, NJ 08512